Piperacillin/Tazobactam vs Meropenem for Infections

(VPS Trial)

This trial compares two common antibiotics, Piperacillin/Tazobactam and Meropenem, to assess their impact on kidney health in patients with serious infections. By determining which antibiotic combination is safer, doctors can make more informed treatment decisions. Hospitalized patients with serious infections who require these antibiotics may qualify for participation. As a Phase 4 trial, this research examines an already FDA-approved treatment to understand its benefits for a broader patient population, providing an opportunity to contribute to safer antibiotic use.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that both piperacillin/tazobactam and meropenem are generally well-tolerated treatments. Piperacillin/tazobactam is considered safe; one study showed that 93% of patients experienced improvement in their infection symptoms. Safety results were similar across different antibiotic treatments. This medication is often used for various infections in both adults and children.

Researchers are excited about these treatments because Piperacillin/Tazobactam and Meropenem offer distinct approaches to fighting infections often treated with antibiotics like amoxicillin or ceftriaxone. Piperacillin/Tazobactam combines a broad-spectrum penicillin with a beta-lactamase inhibitor, which helps it tackle bacteria that have become resistant to other antibiotics. On the other hand, Meropenem is a carbapenem antibiotic known for its potency against a wide range of bacteria, including those that are hard to treat. Both treatments are being evaluated for their effectiveness in combination with vancomycin, potentially offering more robust solutions for severe infections.

This trial will compare the effectiveness of two antibiotics, Piperacillin/Tazobactam and Meropenem, for treating infections. Studies have shown that Meropenem, one of the antibiotics tested in this trial, effectively treats serious infections. It works well against bacteria and is often used in hospitals. Research indicates that administering Meropenem slowly over a longer period can lead to better recovery and shorter ICU stays. In contrast, studies on Piperacillin/Tazobactam, the other antibiotic under study, show mixed results. Some studies suggest it works for certain infections, but others have linked it to higher death rates in patients with sepsis. Both antibiotics have FDA approval, but current evidence suggests Meropenem might be more effective and safer in critical cases.⁶⁷⁸⁹¹⁰